<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108753</url>
  </required_header>
  <id_info>
    <org_study_id>MISC-TaTME-RETRO</org_study_id>
    <nct_id>NCT05108753</nct_id>
  </id_info>
  <brief_title>Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China</brief_title>
  <official_title>Short-term Outcomes of Transanal Total Mesorectal Excision With Structured Training Curriculums in China: Retrospective Study of the First Twenty-five Cases in Seven High-volume Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transanal total mesorectal excision (TaTME) is an alternative for mid-low rectal cancer. In&#xD;
      China, this procedure has been performed in high-volume centers with structured training&#xD;
      curriculums. This study aimed to evaluate the short-term outcomes during the initial&#xD;
      implementation of the TaTME procedure in high-volume centers who followed structured training&#xD;
      curriculums in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of anastomotic leakage</measure>
    <time_frame>thirty days after surgery</time_frame>
    <description>according to the International Rectal Cancer Study Group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of Defecation disorders</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>A Wexner score &gt;10 indicated the existence of defecation dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of positive distal resection margin</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>A positive distal resection margin (DRM) was diagnosed with the presence of tumor cells within 1mm from the DRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of positivecircumferential resection margin</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>The positive circumferential resection margin (CRM) was defined as the presence of tumor cells within 1 mm from the CRM</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">175</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>5 patients underwent TaTME under proctoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>the first 10 patients underwent TaTME without proctoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>the second 10 patients underwent TaTME without proctoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procedure/Surgery</intervention_name>
    <description>Transanal Total Mesorectal Excision</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        rectal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 75 years&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) score I to III&#xD;
&#xD;
          -  A biopsy proven histological diagnosis of rectal carcinoma&#xD;
&#xD;
          -  Undergoing transanal total mesorectal excision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Synchronous rectal carcinoma&#xD;
&#xD;
          -  History of colorectal cancer or other malignant tumors&#xD;
&#xD;
          -  Clinical evidence of metastasis&#xD;
&#xD;
          -  Emergency procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Minimally Invasive Surgery Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

